Jamie Whelan

Jamie Whelan

Auto-generated profile, based on publicly available information

Jamie Whelan

Chemistry Program, New York University Abu Dhabi (NYUAD), Abu Dhabi 129188, United Arab Emirates

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
FBFarah Benyettou
Farah Benyettou
MKMostafa Khair
Mostafa Khair
TPTHIRUMURUGAN PRAKASAM
THIRUMURUGAN PRAKASAM
SVSabu Varghese
Sabu Varghese
ZMZineb Matouk
Zineb Matouk
ATAli Trabolsi
Ali Trabolsi
This study presents the use of nanoscale covalent organic frameworks (nCOFs) conjugated with tumor-targeting peptides for the targeted therapy of triple-negative breast cancer (TNBC). While peptides have previously been used for targeted delivery, their conjugation with COFs represents an innovative approach in this field. In particular, we have developed alkyne-functionalized nCOFs chemically modified with cyclic RGD peptides (Alkyn-nCOF-cRGD). This configuration is designed to specifically target αvβ3 integrins that are overexpressed in TNBC cells. These nCOFs exhibit excellent biocompatibility and are engineered to selectively disintegrate under acidic conditions, allowing for precise and localized drug release in tumor environment. Doxorubicin, a chemotherapeutic agent, has been encapsulated in these nCOFs with high loading efficiency. The therapeutic potential of Alkyn-nCOF-cRGD has been demonstrated in vitro and in vivo models. It shows significantly improved drug uptake and targeted cell death in TNBC, highlighting the efficacy of receptor-mediated endocytosis and pH-controlled drug release. This strategy leverages the unique properties of nCOFs with targeted drug delivery to achieve significant advances in personalized cancer therapy and set a new standard for precision chemotherapeutic delivery.

19 June 2018 in Energy & Fuels
Verified
Journal Article
Closed access
JWJamie Whelan
Jamie Whelan
MKMarios Katsiotis
Marios Katsiotis
SSSamuel Stephen
Samuel Stephen
GLGisha Elizabeth Luckachan
Gisha Elizabeth Luckachan
ATAnjana Tharalekshmy
Anjana Tharalekshmy
SASaeed M. Alhassan
Saeed M. Alhassan

2 May 2022 in Energy & Fuels
Verified
Journal Article
Closed access
TKTim Kahs
Tim Kahs
GRGijo Raj
Gijo Raj
JWJamie Whelan
Jamie Whelan
ELEdward Larkin
Edward Larkin
PCPatrick Commins
Patrick Commins
PNPanče Naumov
Panče Naumov

27 April 2024 in Heliyon
Verified
Journal Article
Open access
NKNawel Kaddour
Nawel Kaddour
FBFarah Benyettou
Farah Benyettou
KMKawtar Moulai
Kawtar Moulai
AMAbdelouahab Mebarki
Abdelouahab Mebarki
KAKatia Allal-Taouli
Katia Allal-Taouli
NSNassima Amal Soulimane
Nassima Amal Soulimane
Complications associated with Type 1 diabetes (T1D) have complex origins that revolve around chronic hyperglycemia; these complications involve hemostasis disorders, coagulopathies, and vascular damage. Our study aims to develop innovative approaches to minimize these complications and to compare the outcomes of the new approach with those of traditional methods. To achieve our objective, we designed novel nanoparticles comprising covalent organic frameworks (nCOF) loaded with insulin, termed nCOF/Insulin, and compared it to subcutaneous insulin to elucidate the influence of insulin delivery methods on various parameters, including bleeding time, coagulation factors, platelet counts, cortisol plasma levels, lipid profiles, and oxidative stress parameters. Traditional subcutaneous insulin injections exacerbated hemostasis disorder and vascular injuries in streptozotocin (STZ)-induced diabetic rats through increasing plasma triglycerides and lipid peroxidation. Conversely, oral delivery of nCOF/Insulin ameliorated hemostatic disorders and restored the endothelial oxidant/antioxidant balance by reducing lipid peroxidation and enhancing the lipid profile. Our study pioneers the understanding of how STZ-induced diabetes disrupts bleeding time, induces a hypercoagulable state, and causes vascular damage through lipid peroxidation. Additionally, it provides the first evidence for the involvement of subcutaneous insulin treatment in exacerbating vascular and hemostasis disorders in type 1 diabetes (T1D). Introducing an innovative oral insulin delivery via the nCOF approach represents a potential paradigm shift in diabetes management and patient care and promises to improve treatment strategies for type 1 Diabetes.